{"id":"NCT01188343","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers","officialTitle":"Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2012-07","completion":"2012-12","firstPosted":"2010-08-25","resultsPosted":"2014-08-15","lastUpdate":"2014-08-15"},"enrollment":542,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis","Measles","Mumps","Rubella"],"interventions":[{"type":"BIOLOGICAL","name":"Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus","otherNames":["JE-CV","MMR II®"]},{"type":"BIOLOGICAL","name":"Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus","otherNames":["JE-CV","MMR II®"]},{"type":"BIOLOGICAL","name":"Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus","otherNames":["JE-CV","MMR II®"]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"}],"summary":"This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at separate visits 6 weeks apart in toddlers aged 12 to 18 months.\n\nPrimary objective:\n\n* To demonstrate the non-inferiority of the antibody responses in terms of seroconversion of the concomitant administration of JE-CV and MMR compared to the antibody responses after the single administration of JE-CV and MMR vaccine.\n\nSecondary objectives:\n\n* To describe the immune response to JE CV and MMR before and after one dose of JE CV and MMR vaccine, respectively.\n* To describe the safety of a single dose of JE-CV and MMR vaccine (given separately at a 6-week interval and the safety of the concomitant administration of JE-CV and MMR vaccine in all subjects up to 6 months after last vaccination.","primaryOutcome":{"measure":"Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or Single Administration of JE-CV and MMR Vaccine at 42 Days Following First Vaccination","timeFrame":"Day 0 (pre-vaccination) and Day 42 post-vaccination","effectByArm":[{"arm":"JE-CV + MMR (Group 1)","deltaMin":97.9,"sd":null},{"arm":"MMR + JE-CV (Group 2)","deltaMin":null,"sd":null},{"arm":"JE-CV/MMR (Group 3)","deltaMin":96.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":3,"countries":["Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":102},"commonTop":["Appetite Lost","Crying Abnormal","Irritability","Drowsiness","Somnolence"]}}